Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy PCVX Stock  Free PCVX Stock Alerts

Vaxcyte (PCVX) Financials

Vaxcyte logo
$30.23 -1.81 (-5.65%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$30.12 -0.11 (-0.35%)
As of 04/15/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Vaxcyte

Annual Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -29 -50 -89 -100 -223 -402 -464
Consolidated Net Income / (Loss)		 -29 -50 -89 -100 -223 -402 -464
Net Income / (Loss) Continuing Operations		 -29 -50 -89 -100 -223 -402 -464
Total Pre-Tax Income 		-29 -50 -89 -100 -223 -402 -464
Total Operating Income		 -36 -54 -90 -104 -232 -468 -570
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 54 90 104 232 468 570
Selling, General & Admin Expense		 5.39 8.55 16 25 40 61 93
Research & Development Expense		 30 46 74 78 169 332 477
Other Operating Expenses / (Income)		 - - - 0.00 23 75 0.00
Total Other Income / (Expense), net		 6.05 4.34 0.36 3.59 8.77 66 106
Interest Expense		 0.08 0.04 0.01 0.01 0.00 0.00 0.00
Interest & Investment Income		 0.90 0.63 0.24 0.35 8.36 63 110
Other Income / (Expense), net		 5.22 3.74 0.13 3.25 0.42 2.87 -4.38
Basic Earnings per Share		 ($8.12) ($13.25) ($3.02) ($1.93) ($3.44) ($4.14) ($3.80)
Weighted Average Basic Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 64.88M 97.16M 122.00M
Diluted Earnings per Share		 ($8.12) ($13.25) ($3.02) ($1.93) ($3.44) ($4.14) ($3.80)
Weighted Average Diluted Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 64.88M 97.16M 122.00M
Weighted Average Basic & Diluted Shares Outstanding		 3.63M 3.80M 29.55M 51.92M 80.03M 108.41M 128.76M
Cash Dividends to Common per Share		 - - $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Vaxcyte

This table shows Vaxcyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Consolidated Net Income / (Loss)		 -58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Net Income / (Loss) Continuing Operations		 -58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Total Pre-Tax Income 		-58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Total Operating Income		 -59 -87 -71 -87 -113 -197 -114 -153 -140 -162
Total Operating Expenses		 59 87 71 87 113 197 114 153 140 162
Selling, General & Admin Expense		 11 12 13 14 16 18 20 21 23 29
Research & Development Expense		 48 52 58 73 97 104 95 132 117 134
Total Other Income / (Expense), net		 0.66 8.22 11 19 20 16 19 24 37 25
Interest & Investment Income		 1.19 6.63 11 16 18 17 22 24 28 36
Other Income / (Expense), net		 -0.53 1.59 -0.32 2.36 1.87 -1.04 -2.34 0.44 8.74 -11
Basic Earnings per Share		 ($0.93) ($1.03) ($0.70) ($0.70) ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02)
Weighted Average Basic Shares Outstanding		 61.99M 64.88M 86.21M 98.06M 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M
Diluted Earnings per Share		 ($0.93) ($1.03) ($0.70) ($0.70) ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02)
Weighted Average Diluted Shares Outstanding		 61.99M 64.88M 86.21M 98.06M 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M
Weighted Average Basic & Diluted Shares Outstanding		 78.98M 80.03M 93.71M 93.85M 95.15M 108.41M 108.80M 111.61M 124.64M 128.76M

Annual Cash Flow Statements for Vaxcyte

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 30 -7.11 327 -316 766 -437 -9.36
Net Cash From Operating Activities		 -30 -47 -47 -121 -171 -297 -453
Net Cash From Continuing Operating Activities		 -30 -47 -47 -121 -171 -297 -453
Net Income / (Loss) Continuing Operations		 -29 -50 -89 -100 -223 -402 -464
Consolidated Net Income / (Loss)		 -29 -50 -89 -100 -223 -402 -464
Depreciation Expense		 1.04 1.23 1.41 1.80 2.83 3.16 7.00
Amortization Expense		 - 0.00 0.00 3.06 5.67 -28 -30
Non-Cash Adjustments To Reconcile Net Income		 -4.76 1.96 13 2.25 35 77 16
Changes in Operating Assets and Liabilities, net		 2.75 -0.06 28 -28 8.91 54 18
Net Cash From Investing Activities		 -1.77 -1.20 -1.11 -212 75 -773 -2,006
Net Cash From Continuing Investing Activities		 -1.77 -1.20 -1.11 -212 75 -773 -2,006
Purchase of Property, Plant & Equipment		 -1.77 -1.20 -1.16 -6.56 -5.84 -16 -22
Purchase of Investments		 - 0.00 0.00 -336 -103 -1,330 -3,087
Sale and/or Maturity of Investments		 - 0.00 0.00 131 183 624 1,200
Other Investing Activities, net		 - - - 0.00 0.00 -52 -97
Net Cash From Financing Activities		 62 42 375 18 862 640 2,449
Net Cash From Continuing Financing Activities		 62 42 375 18 862 640 2,449
Issuance of Common Equity		 0.12 0.12 0.41 15 862 644 2,463
Other Financing Activities, net		 -0.28 -1.05 0.57 3.01 -0.86 -3.88 -14
Effect of Exchange Rate Changes		 - -0.34 0.09 -0.44 0.14 -6.69 0.43

Quarterly Cash Flow Statements for Vaxcyte

This table details how cash moves in and out of Vaxcyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 40 556 -454 151 14 -148 214 -93 532 -662
Net Cash From Operating Activities		 -39 -65 -48 -63 -58 -129 -159 -121 -61 -111
Net Cash From Continuing Operating Activities		 -39 -65 -48 -63 -58 -129 -159 -121 -61 -111
Net Income / (Loss) Continuing Operations		 -58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Consolidated Net Income / (Loss)		 -58 -78 -60 -68 -93 -181 -95 -129 -103 -137
Depreciation Expense		 0.68 0.96 0.71 0.75 0.81 0.89 1.00 1.35 1.79 2.86
Amortization Expense		 1.43 0.42 -4.36 -10 -13 -0.31 -8.90 -7.81 -3.40 -9.76
Non-Cash Adjustments To Reconcile Net Income		 12 13 16 12 41 7.51 -34 57 26 -33
Changes in Operating Assets and Liabilities, net		 5.17 -1.30 0.08 3.08 6.48 44 -22 -43 18 66
Net Cash From Investing Activities		 35 -36 -448 -334 22 -14 -451 -80 -917 -557
Net Cash From Continuing Investing Activities		 35 -36 -448 -334 22 -14 -451 -80 -917 -557
Purchase of Property, Plant & Equipment		 -0.84 -1.14 -5.61 2.14 -7.34 -5.25 -5.68 -7.78 -4.95 -4.02
Purchase of Investments		 -18 -71 -484 -433 -210 -204 -688 -351 -1,233 -815
Sale and/or Maturity of Investments		 53 36 41 97 239 247 249 309 354 288
Other Investing Activities, net		 - - 0.00 - - -52 -6.39 -31 -33 -26
Net Cash From Financing Activities		 44 657 42 547 49 2.74 818 110 1,515 4.91
Net Cash From Continuing Financing Activities		 44 657 42 547 49 2.74 818 110 1,515 4.91
Issuance of Common Equity		 43 659 42 546 49 6.61 816 108 1,513 25
Other Financing Activities, net		 0.90 -2.36 -0.23 0.67 -0.45 -3.87 1.72 2.18 2.40 -21
Effect of Exchange Rate Changes		 0.05 0.80 0.02 -0.08 1.05 -7.68 6.06 -1.41 -5.58 1.35

Annual Balance Sheets for Vaxcyte

This table presents Vaxcyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 66 393 324 1,006 1,408 3,511
Total Current Assets		 62 389 256 943 1,096 1,788
Cash & Equivalents		 59 386 69 835 397 388
Short-Term Investments		 - 0.00 177 97 683 1,359
Prepaid Expenses		 2.75 2.80 10 11 16 41
Plant, Property, & Equipment, net		 3.39 3.27 7.95 10 80 198
Total Noncurrent Assets		 0.58 0.55 60 53 232 1,525
Long-Term Investments		 - 0.00 27 27 163 1,388
Other Noncurrent Operating Assets		 0.58 0.55 33 27 70 138
Total Liabilities & Shareholders' Equity		 66 393 324 1,006 1,408 3,511
Total Liabilities		 12 47 40 53 167 205
Total Current Liabilities		 11 47 29 41 145 140
Accounts Payable		 3.38 30 6.76 9.80 15 48
Accrued Expenses		 7.08 17 13 24 113 65
Current Employee Benefit Liabilities		 0.41 0.28 3.46 1.18 11 21
Other Current Liabilities		 0.16 0.00 5.28 5.91 7.11 5.89
Total Noncurrent Liabilities		 0.71 0.12 12 12 22 65
Other Noncurrent Operating Liabilities		 0.69 0.11 12 12 22 65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -106 346 284 954 1,240 3,306
Total Preferred & Common Equity		 -106 346 284 954 1,240 3,306
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -106 346 284 954 1,240 3,306
Common Stock		 2.97 544 583 1,476 2,165 4,698
Retained Earnings		 -109 -199 -299 -522 -924 -1,388
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.24 -0.36 0.18 -3.87

Quarterly Balance Sheets for Vaxcyte

This table presents Vaxcyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 412 1,008 1,503 1,496 2,091 2,087 3,560
Total Current Assets		 370 841 1,310 1,295 1,517 1,481 2,214
Cash & Equivalents		 278 380 531 545 612 519 1,050
Short-Term Investments		 84 442 756 721 875 934 1,130
Prepaid Expenses		 7.53 19 23 30 31 29 33
Plant, Property, & Equipment, net		 9.95 15 16 11 85 126 163
Total Noncurrent Assets		 32 152 176 189 489 480 1,183
Long-Term Investments		 3.98 128 154 169 413 399 1,093
Other Noncurrent Operating Assets		 28 24 22 21 76 81 90
Total Liabilities & Shareholders' Equity		 412 1,008 1,503 1,496 2,091 2,087 3,560
Total Liabilities		 53 63 69 93 107 101 142
Total Current Liabilities		 39 53 60 86 87 83 124
Accounts Payable		 5.49 12 16 16 22 10 18
Accrued Expenses		 24 33 34 57 55 59 84
Current Employee Benefit Liabilities		 3.45 1.88 4.42 6.93 3.09 6.46 12
Other Current Liabilities		 6.43 5.95 5.99 6.03 7.20 7.29 9.64
Total Noncurrent Liabilities		 13 11 9.23 7.78 20 18 18
Other Noncurrent Operating Liabilities		 13 11 9.23 7.78 20 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 359 945 1,433 1,403 1,984 1,986 3,418
Total Preferred & Common Equity		 359 945 1,433 1,403 1,984 1,986 3,418
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 359 945 1,433 1,403 1,984 1,986 3,418
Common Stock		 804 1,527 2,087 2,149 3,001 3,132 4,669
Retained Earnings		 -444 -583 -651 -744 -1,019 -1,148 -1,251
Accumulated Other Comprehensive Income / (Loss)		 -0.66 0.05 -2.52 -2.29 2.89 1.82 0.14

Annual Metrics and Ratios for Vaxcyte

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -67.98% -79.05% -8.52% -133.73% -119.30% -21.85%
EBIT Growth		 0.00% -66.30% -77.46% -12.25% -130.88% -100.64% -23.38%
NOPAT Growth		 0.00% -52.40% -65.42% -15.73% -124.03% -101.52% -21.69%
Net Income Growth		 0.00% -70.51% -77.46% -12.17% -123.31% -80.00% -15.33%
EPS Growth		 0.00% -63.18% 77.21% 36.09% -78.24% -20.35% 8.21%
Operating Cash Flow Growth		 0.00% -54.75% 1.10% -160.34% -40.53% -73.97% -52.51%
Free Cash Flow Firm Growth		 0.00% 0.00% 16.67% -352.22% -18.96% -123.64% -73.66%
Invested Capital Growth		 0.00% 0.00% -700.89% 127.09% -139.45% 43.55% 7,129.62%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -8.74% -33.95% -30.09% 2.75%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -9.90% -32.06% -31.99% 4.07%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.14% -32.32% -30.76% 5.71%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -8.48% -28.44% -34.31% 8.61%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -143.57% -16.22% -23.95% 17.57%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 7.24% -49.74% -9.03% -27.27% 3.70%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -14.81% -45.85% 4.47%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 188.47% 37.43% 92.28% 18.33%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.92% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.27% 98.83% 99.74% 99.66% 96.40% 86.48% 80.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -93.21% -44.63% -31.78% -36.12% -36.67% -20.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,133.08% 0.00% 0.00% -334.43%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 183.82% -26.74% -31.78% -36.12% -36.67% -20.41%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 47.26% -25.80% -35.24% -23.44% -32.43% -14.03%
Net Operating Profit after Tax (NOPAT)		 -25 -38 -63 -73 -163 -328 -399
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -41.94% -11.91% -8.34% -9.90% -6.78% -2.98%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -17.05% -26.41% -12.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -30 -50 -89 -100 -232 -465 -574
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -49 -88 -96 -223 -490 -597
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.91 4.42 3.97 4.82 3.09
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.91 4.42 3.97 4.82 3.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 89.90 0.00 0.00 41.31
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.09 -1.11 -1.05 -0.99 -1.00 -0.96
Leverage Ratio		 0.00 1.22 1.15 1.14 1.08 1.10 1.08
Compound Leverage Factor		 0.00 1.20 1.14 1.13 1.04 0.95 0.87
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 297.22% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -197.22% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.35 16.87 17.22 42.82 20.21 29.26
Noncontrolling Interest Sharing Ratio		 0.00% 297.22% 40.10% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 5.58 8.30 8.93 23.26 7.54 12.75
Quick Ratio		 0.00 5.34 8.24 8.57 22.98 7.43 12.46
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -33 -27 -124 -147 -330 -572
Operating Cash Flow to CapEx		 -1,718.33% -3,945.19% -4,219.73% -1,859.29% -2,920.68% -1,847.78% -2,018.22%
Free Cash Flow to Firm to Interest Expense		 0.00 -821.70 -3,912.67 -17,693.86 -73,668.10 0.00 0.00
Operating Cash Flow to Interest Expense		 -406.21 -1,178.63 -6,661.14 -17,341.86 -85,298.50 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -429.85 -1,208.50 -6,819.00 -18,274.57 -88,219.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -5.04 -40 11 -4.31 -2.43 171
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.04 -35 51 -15 1.88 174
Enterprise Value (EV)		 0.00 381 968 983 2,829 4,733 7,068
Market Capitalization		 280 280 1,354 1,256 3,787 5,976 10,203
Book Value per Share		 $0.00 ($28.03) $6.79 $5.38 $12.07 $13.04 $26.52
Tangible Book Value per Share		 $0.00 ($28.03) $6.79 $5.38 $12.07 $13.04 $26.52
Total Capital		 0.00 54 346 284 954 1,240 3,306
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -59 -386 -273 -958 -1,243 -3,135
Capital Expenditures (CapEx)		 1.77 1.20 1.11 6.53 5.84 16 22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.31 -44 -18 -29 -130 -99
Debt-free Net Working Capital (DFNWC)		 0.00 51 342 228 902 951 1,648
Net Working Capital (NWC)		 0.00 51 342 228 902 951 1,648
Net Nonoperating Expense (NNE)		 4.61 12 27 28 61 75 65
Net Nonoperating Obligations (NNO)		 0.00 -59 -386 -273 -958 -1,243 -3,135
Total Depreciation and Amortization (D&A)		 1.04 1.23 1.41 4.86 8.51 -25 -23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) ($3.44) ($4.14) ($3.80)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 56.31M 64.88M 97.16M 122.00M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) ($3.44) ($4.14) ($3.80)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 56.31M 64.88M 97.16M 122.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.93) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 51.92M 80.03M 108.41M 128.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -38 -63 -73 -163 -328 -399
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -404.17 -1,260.23 -12,779.14 -14,345.14 -115,919.50 0.00 0.00
NOPAT to Interest Expense		 -331.64 -947.68 -8,958.10 -10,367.00 -81,289.60 0.00 0.00
EBIT Less CapEx to Interest Expense		 -427.81 -1,290.10 -12,937.00 -15,277.86 -118,840.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -355.28 -977.55 -9,115.96 -11,299.71 -84,210.10 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Vaxcyte

This table displays calculated financial ratios and metrics derived from Vaxcyte's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -124.52% -209.66% -108.02% -102.17% -116.26% -135.81% -65.94% -68.73% -7.74% 8.55%
EBIT Growth		 -121.63% -196.11% -84.21% -73.29% -88.06% -132.65% -63.35% -79.91% -18.01% 12.31%
NOPAT Growth		 -117.35% -190.06% -81.52% -81.99% -92.95% -127.18% -60.79% -75.54% -23.80% 17.55%
Net Income Growth		 -117.61% -173.26% -55.09% -40.81% -59.99% -131.65% -57.16% -88.33% -11.29% 24.18%
EPS Growth		 -82.35% -87.27% -2.94% 12.50% 2.15% -77.67% -21.43% -57.14% 8.79% 44.26%
Operating Cash Flow Growth		 -35.66% -27.65% -72.15% -60.36% -49.29% -97.50% -233.66% -93.48% -5.49% 13.52%
Free Cash Flow Firm Growth		 -17.69% 37.16% 52.23% 22.59% -17.24% -207.67% -351.24% -413.30% -403.09% -105.70%
Invested Capital Growth		 44.22% -139.45% -170.53% -244.27% -357.52% 43.55% 1,757.18% 1,909.98% 558.57% 7,129.62%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -22.27% -46.69% 10.38% -25.38% -30.79% -59.95% 36.74% -27.49% 16.48% -35.76%
EBIT Q/Q Growth		 -20.80% -43.78% 15.85% -18.57% -31.10% -77.87% 40.92% -30.59% 14.00% -32.17%
NOPAT Q/Q Growth		 -22.33% -47.79% 17.77% -22.41% -29.70% -74.01% 41.80% -33.64% 8.54% -15.90%
Net Income Q/Q Growth		 -19.34% -34.76% 22.53% -13.03% -35.59% -95.11% 47.45% -35.45% 19.87% -32.93%
EPS Q/Q Growth		 -16.25% -10.75% 32.04% 0.00% -30.00% -101.10% 53.55% -29.41% 24.55% -22.89%
Operating Cash Flow Q/Q Growth		 1.48% -69.19% 26.88% -31.56% 8.28% -123.83% -23.53% 23.71% 49.99% -83.50%
Free Cash Flow Firm Q/Q Growth		 25.75% 2.39% 17.22% -29.04% -12.44% -156.16% -21.41% -46.78% -10.21% -4.74%
Invested Capital Q/Q Growth		 -234.11% 37.43% -17.86% -45.89% -325.30% 92.28% 3,560.07% 59.34% 7.75% 18.33%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.62% 100.00% 100.00% 100.00% 100.00% 100.00% 99.98% 100.00% 100.02%
Interest Burden Percent		 97.99% 92.19% 84.55% 80.60% 83.36% 91.45% 81.34% 84.39% 78.61% 79.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.31% -36.12% -37.56% -29.42% -34.00% -36.67% -29.83% -29.08% -21.06% -20.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -531.03% -406.59% -414.24% -334.43%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -52.31% -36.12% -37.56% -29.42% -34.00% -36.67% -29.83% -29.08% -21.06% -20.41%
Return on Equity Simple (ROE_SIMPLE)		 -48.43% 0.00% -25.93% -18.47% -21.35% 0.00% -22.02% -25.03% -14.85% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -61 -50 -61 -79 -138 -80 -107 -98 -114
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.94% -2.84% -1.63% -0.81% -1.50% -3.92% -1.05% -1.31% -0.22% -1.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.35% - - - -11.10% - - - -3.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -59 -85 -72 -85 -111 -198 -117 -153 -131 -173
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -84 -75 -94 -123 -197 -125 -159 -133 -180
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.96 3.97 3.18 3.26 3.41 4.82 3.28 4.14 3.73 3.09
Price to Tangible Book Value (P/TBV)		 3.96 3.97 3.18 3.26 3.41 4.82 3.28 4.14 3.73 3.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 54.62 47.42 65.57 41.31
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -0.99 -1.00 -1.00 -1.02 -1.00 -0.97 -0.96 -0.98 -0.96
Leverage Ratio		 1.15 1.08 1.08 1.06 1.08 1.10 1.06 1.05 1.05 1.08
Compound Leverage Factor		 1.13 0.99 0.91 0.86 0.90 1.01 0.86 0.89 0.82 0.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.17 43.30 28.29 40.64 30.78 20.84 36.29 48.53 53.94 29.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 9.41 23.26 15.94 21.76 15.14 7.54 17.42 17.88 17.88 12.75
Quick Ratio		 9.21 22.98 15.58 21.37 14.79 7.43 17.07 17.53 17.61 12.46
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -46 -45 -38 -48 -54 -140 -169 -249 -274 -287
Operating Cash Flow to CapEx		 -4,572.72% -5,721.14% -850.24% 0.00% -784.14% -2,451.66% -2,802.47% -1,560.13% -1,227.17% -2,770.48%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -6.89 -4.31 -5.08 -7.41 -32 -2.43 84 134 145 171
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.46 -15 -12 -13 -25 1.88 89 142 176 174
Enterprise Value (EV)		 1,057 2,829 2,050 3,239 3,350 4,733 4,600 6,363 9,481 7,068
Market Capitalization		 1,424 3,787 3,000 4,680 4,784 5,976 6,500 8,215 12,754 10,203
Book Value per Share		 $6.06 $12.07 $11.80 $15.30 $14.95 $13.04 $17.76 $18.26 $30.62 $26.52
Tangible Book Value per Share		 $6.06 $12.07 $11.80 $15.30 $14.95 $13.04 $17.76 $18.26 $30.62 $26.52
Total Capital		 359 954 945 1,433 1,403 1,240 1,984 1,986 3,418 3,306
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -366 -958 -950 -1,441 -1,434 -1,243 -1,900 -1,852 -3,273 -3,135
Capital Expenditures (CapEx)		 0.84 1.14 5.61 -2.14 7.34 5.25 5.68 7.78 4.95 4.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -32 -29 -34 -37 -56 -130 -57 -54 -90 -99
Debt-free Net Working Capital (DFNWC)		 330 902 788 1,250 1,210 951 1,430 1,399 2,090 1,648
Net Working Capital (NWC)		 330 902 788 1,250 1,210 951 1,430 1,399 2,090 1,648
Net Nonoperating Expense (NNE)		 17 17 11 7.34 14 43 15 22 5.18 24
Net Nonoperating Obligations (NNO)		 -366 -958 -950 -1,441 -1,434 -1,243 -1,900 -1,852 -3,273 -3,135
Total Depreciation and Amortization (D&A)		 2.12 1.38 -3.65 -9.44 -12 0.58 -7.90 -6.46 -1.61 -6.89
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.93) ($1.03) ($0.70) ($0.70) ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 61.99M 64.88M 86.21M 98.06M 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M
Adjusted Diluted Earnings per Share		 ($0.93) ($1.03) ($0.70) ($0.70) ($0.91) ($1.83) ($0.85) ($1.10) ($0.83) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding		 61.99M 64.88M 86.21M 98.06M 101.67M 97.16M 111.69M 117.26M 123.69M 122.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 78.98M 80.03M 93.71M 93.85M 95.15M 108.41M 108.80M 111.61M 124.64M 128.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -61 -50 -61 -79 -138 -80 -107 -98 -114
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Vaxcyte's Financials

When does Vaxcyte's financial year end?

According to the most recent income statement we have on file, Vaxcyte's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Vaxcyte's net income changed over the last 6 years?

Vaxcyte's net income appears to be on an upward trend, with a most recent value of -$463.93 million in 2024, rising from -$29.49 million in 2018. The previous period was -$402.27 million in 2023.

What is Vaxcyte's operating income?
Vaxcyte's total operating income in 2024 was -$569.55 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $569.55 million
How has Vaxcyte revenue changed over the last 6 years?

Over the last 6 years, Vaxcyte's total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Vaxcyte have?

Vaxcyte's total liabilities were at $205.50 million at the end of 2024, a 22.7% increase from 2023, and a 1,647.3% increase since 2019.

How much cash does Vaxcyte have?

In the past 5 years, Vaxcyte's cash and equivalents has ranged from $58.98 million in 2019 to $834.66 million in 2022, and is currently $387.88 million as of their latest financial filing in 2024.

How has Vaxcyte's book value per share changed over the last 6 years?

Over the last 6 years, Vaxcyte's book value per share changed from 0.00 in 2018 to 26.52 in 2024, a change of 2,652.4%.

Remove Ads

Related Companies

This page (NASDAQ:PCVX) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...
Crypto 101 Media | Sponsored
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
First look: The $3,500 iPhone
Did you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...
Stansberry Research | Sponsored